These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25505650)

  • 1. Computational pharmacokinetics at a crossroads.
    Bois FY
    In Silico Pharmacol; 2013; 1():5. PubMed ID: 25505650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico pharmacology for drug discovery: applications to targets and beyond.
    Ekins S; Mestres J; Testa B
    Br J Pharmacol; 2007 Sep; 152(1):21-37. PubMed ID: 17549046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.
    Poggesi I; Snoeys J; Van Peer A
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):631-5. PubMed ID: 24517185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.
    Ekins S; Mestres J; Testa B
    Br J Pharmacol; 2007 Sep; 152(1):9-20. PubMed ID: 17549047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving predictive modeling in pediatric drug development: pharmacokinetics, pharmacodynamics, and mechanistic modeling.
    Slikker W; Young JF; Corley RA; Dorman DC; Conolly RB; Knudsen TB; Erstad BL; Luecke RH; Faustman EM; Timchalk C; Mattison DR
    Ann N Y Acad Sci; 2005 Aug; 1053():505-18. PubMed ID: 16179559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
    Abdel-Rahman SM; Kauffman RE
    Annu Rev Pharmacol Toxicol; 2004; 44():111-36. PubMed ID: 14744241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational miRNomics.
    Allmer J; Yousef M
    J Integr Bioinform; 2016 Dec; 13(5):1-2. PubMed ID: 29216003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico methods for predicting drug-drug interactions with cytochrome P-450s, transporters and beyond.
    Ai N; Fan X; Ekins S
    Adv Drug Deliv Rev; 2015 Jun; 86():46-60. PubMed ID: 25796619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?
    Thomas AM; Atkinson TJ
    J Pain; 2018 Jan; 19(1):1-9. PubMed ID: 28842369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
    Fleisher B; Brown AN; Ait-Oudhia S
    Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on computational oral absorption simulation.
    Dressman JB; Thelen K; Willmann S
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1345-64. PubMed ID: 21939427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-based approaches to in silico pharmacology.
    Vidal D; Garcia-Serna R; Mestres J
    Methods Mol Biol; 2011; 672():489-502. PubMed ID: 20838981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: Beyond the reduction of animal model use.
    Huynh L; Masereeuw R; Friedberg T; Ingelman-Sundberg M; Manivet P
    Drug Discov Today; 2009 Apr; 14(7-8):401-5. PubMed ID: 19340929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part II: The body in a Hilbertian space.
    Jacob A; Pratuangdejkul J; Buffet S; Launay JM; Manivet P
    Drug Discov Today; 2009 Apr; 14(7-8):406-12. PubMed ID: 19340930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.
    Gabrielsson J; Andersson K; Tobin G; Ingvast-Larsson C; Jirstrand M
    Comput Methods Programs Biomed; 2014 Mar; 113(3):815-29. PubMed ID: 24461798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of in silico approaches to predicting drug--drug interactions.
    Ekins S; Wrighton SA
    J Pharmacol Toxicol Methods; 2001; 45(1):65-9. PubMed ID: 11489666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic modeling in drug development.
    Sheiner LB; Steimer JL
    Annu Rev Pharmacol Toxicol; 2000; 40():67-95. PubMed ID: 10836128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.